As part of the Cambridge Biotech week, KPMG and One Nucleus are pleased to invite you to a luncheon where we will be sharing the latest developments of the biotech ecosystem in Hong Kong and the opportunities for early stage and mature biotech companies in the UK.
Over the past two years, over US$13 billion and a variety of policies were launched by the Hong Kong government to spur technology innovation in the City. Among those developments include the new public listing regime for pre-revenue biotech companies on the Hong Kong Exchange, two research clusters on healthcare and on artificial intelligence and robotics, and and the release of the Outline Development Plan for the Guangdong-Hong Kong-Macao Greater Bay Area by China's central government. The Greater Bay Area, comprising nine cities in Guangdong's Pearl River Delta, as well as Hong Kong and Macau, will cooperate and invest significant resources to become a globally influential international innovation and technology hub.
Our discussion will be led by representatives from the Hong Kong Exchanges and Clearing (HKEx), and Hong Kong Science and Technology Park (HKSTP) - a public corporation entrusted by the Government of Hong Kong to spur innovation and advancements in the fields of Biomedical Technology, Electronics, Green Technology, Information and Communications Technology, Material and Precision Engineering.